These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 25473901)

  • 1. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
    Scheffler M; Bos M; Gardizi M; König K; Michels S; Fassunke J; Heydt C; Künstlinger H; Ihle M; Ueckeroth F; Albus K; Serke M; Gerigk U; Schulte W; Töpelt K; Nogova L; Zander T; Engel-Riedel W; Stoelben E; Ko YD; Randerath W; Kaminsky B; Panse J; Becker C; Hellmich M; Merkelbach-Bruse S; Heukamp LC; Büttner R; Wolf J
    Oncotarget; 2015 Jan; 6(2):1315-26. PubMed ID: 25473901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
    Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
    Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens.
    Bar J; Damianovich M; Hout Siloni G; Dar E; Cohen Y; Perelman M; Ben Nun A; Simansky D; Yellin A; Urban D; Onn A
    Clin Lung Cancer; 2014 Mar; 15(2):159-65. PubMed ID: 24370118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIK3CA mutations as prognostic factor in squamous cell lung carcinoma.
    McGowan M; Hoven AS; Lund-Iversen M; Solberg S; Helland Å; Hirsch FR; Brustugun OT
    Lung Cancer; 2017 Jan; 103():52-57. PubMed ID: 28024696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
    Driver BR; Portier BP; Mody DR; Deavers M; Bernicker EH; Kim MP; Teh BS; Santacruz JF; Kopas L; Munden RF; Cagle PT
    Arch Pathol Lab Med; 2016 Apr; 140(4):312-7. PubMed ID: 26430808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
    Wang L; Hu H; Pan Y; Wang R; Li Y; Shen L; Yu Y; Li H; Cai D; Sun Y; Chen H
    PLoS One; 2014; 9(2):e88291. PubMed ID: 24533074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.
    Young G; Wang K; He J; Otto G; Hawryluk M; Zwirco Z; Brennan T; Nahas M; Donahue A; Yelensky R; Lipson D; Sheehan CE; Boguniewicz AB; Stephens PJ; Miller VA; Ross JS
    Cancer Cytopathol; 2013 Dec; 121(12):688-94. PubMed ID: 23893923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patients.
    Maeng CH; Lee HY; Kim YW; Choi MK; Hong JY; Jung HA; Lee KS; Kim H; Kwon OJ; Sun JM; Ahn JS; Park K; Um SW; Ahn MJ
    Anticancer Res; 2013 Nov; 33(11):5127-33. PubMed ID: 24222160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
    Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
    Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients.
    Tuononen K; Kero M; Mäki-Nevala S; Sarhadi VK; Tikkanen M; Wirtanen T; Rönty M; Knuuttila A; Knuutila S
    Genes Chromosomes Cancer; 2014 Nov; 53(11):895-901. PubMed ID: 24942490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA mutation status in Japanese lung cancer patients.
    Kawano O; Sasaki H; Endo K; Suzuki E; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
    Lung Cancer; 2006 Nov; 54(2):209-15. PubMed ID: 16930767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic profiling in a homogeneous molecular subtype of non-small cell lung cancer: An effort to explore new drug targets.
    Veldore VH; Patil S; Satheesh CT; Shashidhara HP; Tejaswi R; Prabhudesai SA; Krishnamoorthy N; Hazarika D; Naik R; Rao RM; Ajai Kumar BS
    Indian J Cancer; 2015; 52(2):243-8. PubMed ID: 26853422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer.
    Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Michnar M; Trojanowski T; Milanowski J
    Clin Transl Oncol; 2016 Oct; 18(10):1039-43. PubMed ID: 26860843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA Mutations Detected in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer.
    Nicoś M; Krawczyk P; Powrózek T; Szudy P; Jarosz B; Sawicki M; Szumiło J; Trojanowski T; Milanowski J
    Anticancer Res; 2016 May; 36(5):2243-9. PubMed ID: 27127129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of TP53 mutations on the prognosis of patients with early stage non-small cell lung cancer may depend on the intratumor heterogeneity of the mutations.
    Lee SY; Jeon HS; Hwangbo Y; Jeong JY; Park JY; Lee EJ; Jin G; Shin KM; Yoo SS; Lee J; Lee EB; Cha SI; Kim CH; Park JY
    Mol Carcinog; 2015 Feb; 54(2):93-101. PubMed ID: 24038464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.
    Yagishita S; Horinouchi H; Katsui Taniyama T; Nakamichi S; Kitazono S; Mizugaki H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Sumi M; Shiraishi K; Kohno T; Furuta K; Tsuta K; Tamura T
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):140-8. PubMed ID: 25442336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods.
    Shi X; Wu H; Lu J; Duan H; Liu X; Liang Z
    Sci Rep; 2016 Feb; 6():22297. PubMed ID: 26923333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing.
    He Y; Zhang X; Wang L; Tian Z; Liu Q; Yao J; Liu Y; Li C; Min L; Shan B
    Int J Oncol; 2016 Dec; 49(6):2351-2358. PubMed ID: 27748796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hot spot mutations in Finnish non-small cell lung cancers.
    Mäki-Nevala S; Sarhadi VK; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuuttila A; Knuutila S
    Lung Cancer; 2016 Sep; 99():102-10. PubMed ID: 27565922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.